durvalumab,paclitaxel,carboplatin,cisplatin,gemcitabine,pemetrexed
astrazeneca
['durva', 'aegean']
aegean phase 3 trial with perioperative durvalumab+ neoadj chemo presented by dr. heymach at #aacr23 49% n2+, efs nr vs 25.9 mo (hr 0.68, p 0.0039), 24-mo efs 63% vs 52% (median fup 11.7 mo, 31.9% maturity), pcr rate 17% vs 4%, mpr 33% vs 12% in durva and pbo arm respect. 
MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM